Odyssey Therapeutics, Inc. (ODTX)
19.00
+0.88
(+4.86%)
USD |
NASDAQ |
Oct 09, 16:00
18.92
-0.08
(-0.42%)
After-Hours: 20:00
Odyssey Therapeutics Net Income (Quarterly) : -52.79M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -52.79M |
| March 31, 2026 | -38.26M |
| June 30, 2025 | -41.24M |
| Date | Value |
|---|---|
| March 31, 2025 | -38.44M |
| December 31, 2024 | -35.93M |
| December 31, 2023 | -28.86M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 52.79M |
| EPS Diluted (Quarterly) | -1.102 |
| Enterprise Value | 624.18M |
| Earnings Yield | -18.72% |
| Normalized Earnings Yield | -18.52 |